SUBSCRIBE
SUBSCRIBE
News   Drug Development

Basilea Pharmaceutica Reports 2006 Interim Results Reflecting Successful Investment In Late-stage Development Programs

August 24, 2006 | 
1 min read

BASEL, Switzerland, Aug. 24, 2006 (PRIMEZONE) -- Basilea Pharmaceutica Ltd. (SWX:BSLN) reports interim financial results. Three compounds planned to be in phase III by year-end.

Clinical research Phase III Earnings Europe
MORE ON THIS TOPIC
vial of vaccine for the vaccination plan against diseases in the China. Doctor with a vial with doses of the vaccine in front of the China flag
Earnings
Merck’s Gardasil Woes Grow as China Trade War Heats Up
February 4, 2025
 · 
4 min read
 · 
Annalee Armstrong
Pictured: Regeneron logo on a light brown building
Earnings
Regeneron Misses on Eylea, Dupixent Sales; Issues First-Ever Dividends
February 4, 2025
 · 
2 min read
 · 
Tristan Manalac
Young White Woman at home Holding Two Pain Killer Pills in Her Hand Palm After Spilling from Bottle and Glass of Water. Concept of Pain Relief, Addiction to Opioids and NSAIDs
Pain
Algiax’s Non-Opioid Drug Reduces Neuropathic Pain in Mid-Stage Trial
February 4, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Weigh scales on pink background, top view with space for text. Overweight concept
Obesity
UK Pharmacies Regulator Wants Tighter Checks on Weight Loss Injections
February 4, 2025
 · 
2 min read
 · 
Tristan Manalac